EFFECTIVENESS OF MAINTENANCE THERAPY AFTER THE END OF THE FIRST LINE OF TREATMENT FOR PATIENTS WITH METASTATIC COLORECTAL CANCER – THE RESULTS OF A POPULATION-BASED STUDY

Aim. To evaluate the effectiveness of different regimens of maintenance chemotherapy after the first line of treatment for patients with metastatic colorectal cancer.

Materials and methods. We performed retrospective analyses of the data from 432 patients from 17 clinics in 14 regions of the Russian Federation who started systemic therapy for metastatic cancer in 2013. The main inclusion criterion was objective response or stabilization after the first 16 weeks of first-line therapy. Four groups of patients were compared, depending on the nature of maintenance therapy: those receiving fluoropyrimidines, a combination of fluoropyrimidines with bevacizumab, monotherapy of bevacizumab and monotherapy of anti-EGFR antibodies. The main criteria for assesment of the effectiveness of treatment were progression-free survival and overall survival. The statistical analysis was performed with the SPSS 20.0 sof tware package.

Results. Maintenance therapy after completion of the first 16 weeks of the 1st line of chemotherapy was administered in 126 patients, most of them were treated with fluoropyrimidines (53.1 %). The median overall survival in the maintenance group was 27 versus 21 months in the observation group, p=0.01, HR=0.78 (95 % CI 0.6–1.02) Median progression-free survival in the maintenance group was 11 vs 7 months in the observation group (p<0.001, HR=0.6, 95 % CI 0.5–0.8). The worst results of progression-free survival were observed in the group with monotherapy of bevacizumab – median was 10 months versus 12 months in the fluoropyrimidine monotherapy group, 10 months for the combination of fluoropyrimidine with bevacizumab and 14 months for monotherapy of the anti-EGFR (p=0,9, HR=1.0, 95 % CI 0.9–1.2).

Conclusions. There were no statistical differences in survival with different regimens of maintenance therapy. Monotherapy of bevacizumab in maintenance treatment was associated with the worst sur vival rates.

1. de Gramont A., Figer A., Seymour M. et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000. Vol. 18. P. 2938–2947.

2. Van Cutsem E., Kohne C. H., Lang I. et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 2011. Vol. 29. P. 2011–2019.

3. Cassidy J., Clarke S., Diaz-Rubio E. et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil / folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J. Clin. Oncol. 2008. Vol. 26. P. 2006–2012.

4. Saltz L. B., Clarke S., Diaz-Rubio E. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 2008. Vol. 26. P. 2013–2019.

5. https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf.

6. Van Cutsem E., Cervantes A., Adam R. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 2016. Vol. 27 (8). P. 1386–1422.

7. Maughan T. S., James R. D., Kerr D. J. et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicenter randomised trial. Lancet. 2003. Vol. 361. P. 457–464.

8. Labianca R., Sobrero A., Isa L. et al. Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised “GISCAD” trial. Ann. Oncol. 2011. Vol. 22. P. 1236–1242.

9. Tournigand C., Cervantes A., Figer A. et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer – a GERCOR study. J. Clin. Oncol. 2006. Vol. 24. P. 394–400.

10. Adams R. A., Meade A. M., Seymour M. T. et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol. 2011. Vol. 12. P. 642–653.

11. Chibaudel B., Maindrault-Goebel F., Lledo G. et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J. Clin. Oncol. 2009. Vol. 27. P. 5727–5733.

12. Tournigand C., Chibaudel B., Samson B. et al. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2015. Vol. 16. P. 1493–1505.

13. Diaz-Rubio E., Gomez-Espana A., Massuti B. et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist. 2012. Vol. 17. P. 15–25.

14. Hegewisch-Becker S., Graeven U., Lerchenmuller C. A. et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, openlabel, phase 3 trial. Lancet Oncol. 2015. Vol. 16. P. 1355–1369.

15. Koeberle D., Betticher D. C., von Moos R. et al. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK41 / 06). Ann. Oncol. 2015. Vol. 26. P. 709–714.

16. Simkens L. H., van Tinteren H., May A. et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015. Vol. 385. P. 1843–1852.

17. Wasan H., Meade A. M., Adams R. et al. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet Oncol. 2014. Vol. 15. P. 631–639.

18. Johnsson A., Hagman H., Frodin J. E. et al. A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial. Ann. Oncol. 2013. Vol. 24. P. 2335–2341.

19. Stein A., Atanackovic D., Hildebrandt B. et al. Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer. Br. J. Cancer. 2015. Vol. 113. P. 872–877.

20. Garcia Alfonso P., Benavides M., Sanchez Ruiz A. et al. Phase II study of first-line mFOLFOX plus cetuximab (C) for 8 cycles followed by mFOLFOX plus C or single agent (S / A) C as maintenance therapy in patients (P) with metastatic colorectal cancer (mCRC): The MACRO-2 trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]). Ann. Oncol. 2014. Vol. 25. Suppl. 4. Abstr. 499O.

21. Tveit K. M., Guren T., Glimelius B. et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in fi rst-line treatment of metastatic colorectal cancer: the NORDIC‑VII study. J. Clin. Oncol. 2012. Vol. 30. P. 1755–1762.

22. Fedyanin M. Yu., Tryakin A. A., Tjulandin S. A. Podderzhivayushchee lechenie bol’nykh s metastaticheskim rakom tolstoi kishki posle zaversheniya pervoi linii khimioterapii (Supportive treatment of patients with metastatic colon cancer after completion of the first line of chemotherapy). Effektivnaya farmakoterapiya: onkologiya, gematologiya, radiologiya. 2013. No. 3. P. 44–54 (In Russ.).

23. Luo H. Y., Li Y. H., Wang W. et al. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Ann. Oncol. 2016. Vol. 27 (6). P. 1074–1081.

24. Aparicio T., Ghiringhelli F., Boige V. et al. Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). J. Clin. Oncol. 2018. Vol. 36 (7). P. 674–681.

25. Rivera Herrero F., Bachet J., Modest D. P. et al. Outcomes in patients receiving maintenance therapy in two panitumumab (Pmab) first-line trials for metastatic colorectal cancer (mCRC). Ann. Oncol. 2017. Vol. 28. Suppl 5. P. v158–v208.